Prognostic significance of circulating tumor cells in advanced non-small cell lung cancer patients treated with docetaxel and gemcitabine.


PURPOSE To evaluate the association in the change of circulating tumor cell (CTC) levels and clinical outcomes (PFS and OS) in patients with advanced non-small cell lung cancer (NSCLC) treated homogenously with docetaxel and gemcitabine administered every 2 weeks. METHODS We prospectively evaluated 37 patients for CTC levels at baseline and after 2 months… (More)
DOI: 10.1007/s12094-013-1128-8


  • Presentations referencing similar topics